Login to Your Account



Allicense 2013

Oncology Dominates Biotech Deals in 2012; Changes Loom

By Catherine Shaffer
Staff Writer

Wednesday, May 1, 2013

SAN FRANCISO – One-third of all biotechnology deals in 2012 were for oncology assets, according to Deloitte Recap LLC, a higher percentage than any other therapeutic area.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription